Intensīvā aprūpe un reanimācija
Hemostāzes kontrole un optimizācija
Antifibrinolītiskie līdzekļi
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (opens new window)
Avots: Lancet 2019;394(10210):1713-23.
Raksts indeksēts: PubMed 31623894
DOI: 10.1016/S0140-6736(19)32233-0
https://www.ncbi.nlm.nih.gov/pubmed/31623894 (opens new window)
Alternatives to allogeneic platelet transfusion. (opens new window)
Avots: Br J Haematol 2016;175(3):381-92.
Raksts indeksēts: PubMed 27650431
DOI: 10.1111/bjh.14338
https://www.ncbi.nlm.nih.gov/pubmed/27650431 (opens new window)
Tranexamic acid: less bleeding and less thrombosis? (opens new window)
Avots: Crit Care 2012;16(3):135.
Raksts indeksēts: PubMed 22748073
DOI: 10.1186/cc11374
https://www.ncbi.nlm.nih.gov/pubmed/22748073 (opens new window)
Tranexamic acid for reducing mortality in emergency and urgent surgery. (opens new window)
Avots: Cochrane Database Syst Rev 2013;(1):CD010245.
Raksts indeksēts: PubMed 23440847
DOI: 10.1002/14651858.CD010245.pub2
https://www.ncbi.nlm.nih.gov/pubmed/23440847 (opens new window)
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (opens new window)
Avots: Lancet 2011;377(9771):1096-101, 1101.e1-2.
Raksts indeksēts: PubMed 21439633
DOI: 10.1016/S0140-6736(11)60278-X
https://www.ncbi.nlm.nih.gov/pubmed/21439633 (opens new window)
Antifibrinolytic drugs for acute traumatic injury. (opens new window)
Avots: Cochrane Database Syst Rev 2011;(1):CD004896.
Raksts indeksēts: PubMed 21249666
DOI: 10.1002/14651858.CD004896.pub3
https://www.ncbi.nlm.nih.gov/pubmed/21249666 (opens new window)
Use of tranexamic acid to reduce bleeding in burns surgery. (opens new window)
Avots: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.
Raksts indeksēts: PubMed 21983540
DOI: 10.1016/j.bjps.2011.09.028
https://www.ncbi.nlm.nih.gov/pubmed/21983540 (opens new window)
Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (opens new window)
Avots: Burns. 2022;48(3):522-28.
Raksts indeksēts: PubMed 35339324
DOI: 10.1016/j.burns.2022.03.002
https://pubmed.ncbi.nlm.nih.gov/35339324/ (opens new window)
Aktivēts rekombinants VII faktors (rFVIIa)
Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (opens new window)
Avots: J Blood Med 2011;2:131-4.
Raksts indeksēts: PubMed 22287872
DOI: 10.2147/JBM.S21609
https://www.ncbi.nlm.nih.gov/pubmed/22287872 (opens new window)
The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (opens new window)
Avots: Transfusion 2009;49 Suppl 5:240S-7S.
Raksts indeksēts: PubMed 19954486
DOI: 10.1111/j.1537-2995.2008.01987.x
https://www.ncbi.nlm.nih.gov/pubmed/19954486 (opens new window)
The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (opens new window)
Avots: Transfusion 2013;53 Suppl 1:91S-5S.
Raksts indeksēts: PubMed 23301979
DOI: 10.1111/trf.12041
https://www.ncbi.nlm.nih.gov/pubmed/23301979 (opens new window)
A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (opens new window)
Avots: Am Surg 2005;71(5):414-5.
Raksts indeksēts: PubMed 15986972
https://www.ncbi.nlm.nih.gov/pubmed/15986972 (opens new window)
Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (opens new window)
Avots: J Trauma 2010;69(3):489-500.
Raksts indeksēts: PubMed 20838118
DOI: 10.1097/TA.0b013e3181edf36e
https://www.ncbi.nlm.nih.gov/pubmed/20838118 (opens new window)
Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (opens new window)
Avots: Ann Surg 2008;248(1):61-8.
Raksts indeksēts: PubMed 18580208
DOI: 10.1097/SLA.0b013e318176c4ec
https://www.ncbi.nlm.nih.gov/pubmed/18580208 (opens new window)
Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (opens new window)
Avots: J Trauma 2006;61(4):1016-8.
Raksts indeksēts: PubMed 17033583
DOI: 10.1097/01.ta.0000239261.48022.f1
https://www.ncbi.nlm.nih.gov/pubmed/17033583 (opens new window)
Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (opens new window)
Avots: ANZ J Surg 2013;83(3):155-60.
Raksts indeksēts: PubMed 23035873
DOI: 10.1111/j.1445-2197.2012.06285.x
https://www.ncbi.nlm.nih.gov/pubmed/23035873 (opens new window)
Recombinant factor VIIa in trauma patients with the 'triad of death.' (opens new window)
Avots: Injury 2012;43(9):1409-14.
Raksts indeksēts: PubMed 21345431
DOI: 10.1016/j.injury.2011.01.033
https://www.ncbi.nlm.nih.gov/pubmed/21345431 (opens new window)
Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (opens new window)
Avots: Injury 2008;39(9):1054-61.
Raksts indeksēts: PubMed 18656871
DOI: 10.1016/j.injury.2008.03.032
https://www.ncbi.nlm.nih.gov/pubmed/18656871 (opens new window)
Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (opens new window)
Avots: Anesthesiology 2003;98(6):1513-5.
Raksts indeksēts: PubMed 12766668
https://www.ncbi.nlm.nih.gov/pubmed/12766668 (opens new window)
Koagulācijas faktoru koncentrāti
Alternatives to allogeneic platelet transfusion. (opens new window)
Avots: Br J Haematol 2016;175(3):381-92.
Raksts indeksēts: PubMed 27650431
DOI: 10.1111/bjh.14338
https://www.ncbi.nlm.nih.gov/pubmed/27650431 (opens new window)
The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (opens new window)
Avots: Transfusion 2013;53 Suppl 1:91S-5S.
Raksts indeksēts: PubMed 23301979
DOI: 10.1111/trf.12041
https://www.ncbi.nlm.nih.gov/pubmed/23301979 (opens new window)
Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (opens new window)
Avots: Thromb Res 2014;134(2):360-8.
Raksts indeksēts: PubMed 24857189
DOI: 10.1016/j.thromres.2014.05.008
https://www.ncbi.nlm.nih.gov/pubmed/24857189 (opens new window)
Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (opens new window)
Avots: Br J Haematol 2013;160(2):228-36.
Raksts indeksēts: PubMed 23151086
DOI: 10.1111/bjh.12118
https://www.ncbi.nlm.nih.gov/pubmed/23151086 (opens new window)
Strategies to reduce the use of blood products: a European perspective. (opens new window)
Avots: Curr Opin Anaesthesiol 2012;25(1):59-65.
Raksts indeksēts: PubMed 22113184
DOI: 10.1097/ACO.0b013e32834dec98
https://www.ncbi.nlm.nih.gov/pubmed/22113184 (opens new window)
Desmopresīns
Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (opens new window)
Avots: Anesthesiology 2008;109(6):1063-76.
Raksts indeksēts: PubMed 19034103
DOI: 10.1097/ALN.0b013e31818db18b
https://www.ncbi.nlm.nih.gov/pubmed/19034103 (opens new window)
Alternatives to allogeneic platelet transfusion. (opens new window)
Avots: Br J Haematol 2016;175(3):381-92.
Raksts indeksēts: PubMed 27650431
DOI: 10.1111/bjh.14338
https://www.ncbi.nlm.nih.gov/pubmed/27650431 (opens new window)
Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (opens new window)
Avots: Blood Rev 2014;28(3):95-102.
Raksts indeksēts: PubMed 24703870
DOI: 10.1016/j.blre.2014.03.001
https://www.ncbi.nlm.nih.gov/pubmed/24703870 (opens new window)
Citi līdzekļi
Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (opens new window)
Avots: JAMA 1987;258(14):1916-9.
Raksts indeksēts: PubMed 3656602
DOI: 10.1001/jama.1987.03400140078028
https://www.ncbi.nlm.nih.gov/pubmed/3656602 (opens new window)
Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (opens new window)
Avots: Blood Coagul Fibrinolysis 2002;13(1):49-52.
Raksts indeksēts: PubMed 11994567
DOI: 10.1097/00001721-200201000-00007
https://www.ncbi.nlm.nih.gov/pubmed/11994567 (opens new window)
Vietējie hemostatiskie līdzekļi
The use of fibrin sealant in burn operations. (opens new window)
Avots: Surgery 2007;142(4 Suppl):S50-4.
Raksts indeksēts: PubMed 18019939
DOI: 10.1016/j.surg.2007.06.026
https://www.ncbi.nlm.nih.gov/pubmed/18019939 (opens new window)
Use of fibrin sealant in thermal injury. (opens new window)
Avots: J Burn Care Rehabil 1997;18(5):429-34.
Raksts indeksēts: PubMed 9313125
DOI: 10.1097/00004630-199709000-00011
https://www.ncbi.nlm.nih.gov/pubmed/9313125 (opens new window)
Viskoelasticitātes testi, lai noteiktu ķirurģisko vai koagulopātijas asiņošanu
Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (opens new window)
Avots: Br J Anaesth 2012;109(3):376-81.
Raksts indeksēts: PubMed 22719014
DOI: 10.1093/bja/aes186
https://www.ncbi.nlm.nih.gov/pubmed/22719014 (opens new window)
Transfusion in trauma: why and how should we change our current practice? (opens new window)
Avots: Curr Opin Anaesthesiol 2009;22(2):305-12.
Raksts indeksēts: PubMed 19390257
DOI: 10.1097/ACO.0b013e3283212c7c
https://www.ncbi.nlm.nih.gov/pubmed/19390257 (opens new window)
Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (opens new window)
Avots: Health Technol Assess 2015;19(58):1-228.
Raksts indeksēts: PubMed 26215747
DOI: 10.3310/hta19580
https://www.ncbi.nlm.nih.gov/pubmed/26215747 (opens new window)